By Deena Beasley (Reuters) - Pfizer Inc, one of several drugmakers racing to commercialize a new class of cholesterol-lowering injections, is also developing an oral pill and vaccine that target the "bad" cholesterol protein, PCSK9, according to Mikael Dolsten, the company's research and development chief. Pfizer expects to begin a trial in humans this year of a small molecule pill designed to target the PCSK9 protein that maintains "bad" LDL cholesterol in the bloodstream, Dolsten said in an interview during the J.P. Morgan Healthcare conference in San Francisco. ...
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment